Next Article in Journal
Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines
Previous Article in Journal
The Biotechnological Applications of Recombinant Single-Domain Antibodies are Optimized by the C-Terminal Fusion to the EPEA Sequence (C Tag)
Previous Article in Special Issue
From Donor to Recipient: Current Questions Relating to Humoral Alloimmunization
Article Menu

Export Article

Open AccessReview
Antibodies 2014, 3(2), 192-204; doi:10.3390/antib3020192

Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A

Department of Pathology and Laboratory Medicine, Medical School, University of Texas Health Science Center at Houston, TX 77030, USA
Program in Molecular Pathology, Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Received: 29 October 2013 / Revised: 1 March 2014 / Accepted: 24 March 2014 / Published: 8 April 2014
(This article belongs to the Special Issue B Cells and Immunological Tolerance)
View Full-Text   |   Download PDF [410 KB, uploaded 8 April 2014]


Immune responses directed against clotting factor FVIII (FVIII) seriously complicate treatments for patients with hemophilia A. This response can manifest in congenital hemophilia A patients who generate inhibitor antibodies that bind and inactivate “transplanted” replacement FVIII, as well as in acquired hemophiliacs, whose immune systems have lost tolerance to self-FVIII. Regardless of the mechanism by which production of anti-FVIII inhibitor antibody is triggered, the maintenance of this deleterious response in both congenital and acquired hemophiliacs likely relies upon FVIII specific memory B cells. In this review, the similarities and differences in the kinetics, specificities, and subclasses of antibodies produced in response to allo- and auto-FVIII is outlined. A brief description of the immune cell interactions that contribute to maintenance of antibody response, focusing on development of memory B cells and/or long lived plasma cells is also presented. As current treatments for inhibitor antibodies are not successful in all patients, a better understanding of the functions and persistence of memory B cells specific for FVIII is required. Herein, both clinical and experimental data regarding the effects of immune tolerance induction on memory B cell subpopulations is discussed. Finally, the outcomes of B cell-specific depletion via rituximab in hemophilia and other autoimmune diseases are discussed to highlight insights into the subpopulations of memory B cells that contribute to the development and maintenance of successful tolerance to FVIII. View Full-Text
Keywords: hemophilia; autoimmunity; FVIII; B cells hemophilia; autoimmunity; FVIII; B cells
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Actor, A.M.; Holley, C.K.; Csencsits-Smith, K. Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A. Antibodies 2014, 3, 192-204.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top